LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. “There remains significant unmet need for new schizophrenia therapies that provide patients rapid relief from ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Detailed price information for Lb Pharmaceuticals Inc (LBRX-Q) from The Globe and Mail including charting and trades.
Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027 Announced plans for pipeline expansion of LB-102 into ne ...
Pivotal Phase 3 NOVA-2 trial in schizophrenia ongoing, topline data expected in 2H 2027 LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. “We are pleased to publish ...
This is a syndicated post stub. MPR, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results